文献速递血管炎其他结缔组织病

抗白介素6受体托珠单抗治疗白塞病相关难治性葡萄膜炎:多中心回顾性研究

Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

多中心回顾性研究纳入11例白塞病相关难治性葡萄膜炎患者(20只患眼),评估托珠单抗疗效。托珠单抗使所有眼部参数快速且持续改善,8例达完全缓解,但仅对3例眼外表现有效。平均随访9.5(标准差8.05)个月,2例因严重输注反应和关节炎加重而停药。

要点

  • 托珠单抗使白塞病相关难治性葡萄膜炎所有眼部参数快速且持续改善。
  • 11例中8例达完全缓解,但仅3例眼外表现有效。
  • 2例因严重输注反应和关节炎加重而停药。

核心结论

  • 托珠单抗可能是白塞病相关难治性葡萄膜炎患者的一种治疗选择。

研究设计与样本

  • 多中心回顾性研究纳入11例白塞病相关葡萄膜炎患者(7例男性,20只患眼),中位年龄35岁,患者对传统和生物免疫抑制剂难治。

主要发现

  • 葡萄膜炎9例为双侧;眼内受累类型为全葡萄膜炎(n=8,其中4例伴视网膜血管炎)、前葡萄膜炎(n=2)和后葡萄膜炎(n=1);7例存在黄斑囊样水肿;病程为复发性(n=7)或慢性(n=4)。
  • 托珠单抗治疗前,患者已接受全身糖皮质激素、传统免疫抑制剂及以下生物制剂:阿达木单抗(n=8)、英夫利西单抗(n=4)、卡那奴单抗(n=1)、戈利木单抗(n=3)、依那西普(n=1)。
  • 托珠单抗以单药或联合传统免疫抑制剂使用,剂量为8 mg/kg静脉注射每4周(n=10)或162 mg皮下注射每周(n=1)。
  • 托珠单抗起病时存在的眼外表现包括:口腔和/或生殖器溃疡(n=7)、关节炎(n=4)、毛囊炎/假性毛囊炎(n=4)、结节性红斑(n=2)、网状青斑(n=1)和神经系统受累(n=2)。
  • 托珠单抗使所有眼部参数快速且持续改善,8例达完全缓解;但眼外表现并非如此,托珠单抗仅对其中3例有效。

关键数值与推荐

  • 托珠单抗给药方案为8 mg/kg静脉注射每4周(n=10)或162 mg皮下注射每周(n=1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy of tocilizumab (TCZ) in refractory uveitis of Behçet's disease (BD). METHODS: Multicentre study of patients with BD-associated uveitis. Patients were refractory to conventional and biologic immunosuppressive drugs. The main outcome measures were intraocular inflammation, macular thickness, visual acuity and corticosteroid-sparing effects. RESULTS: We studied 11 patients (7 men) (20 affected eyes); median age 35 years. Uveitis was bilateral in nine patients. The patterns of ocular involvement were panuveitis (n = 8, with retinal vasculitis in 4), anterior uveitis (n = 2) and posterior uveitis (n = 1). Cystoid macular oedema was present in seven patients. The clinical course was recurrent (n = 7) or chronic (n = 4). Before TCZ, patients had received systemic corticosteroids, conventional immunosuppressants and the following biologic agents: adalimumab (n = 8), infliximab (n = 4), canakimumab (n = 1), golimumab (n = 3), etanercept (n = 1). TCZ was used as monotherapy or combined with conventional immunosuppressants at 8 mg/kg/i.v./4 weeks (n = 10) or 162 mg/s.c./week (n = 1). At TCZ onset the following extraocular manifestations were present: oral and/or genital ulcers (n = 7), arthritis (n = 4), folliculitis/pseudofolliculitis (n = 4), erythema nodosum (n = 2), livedo reticularis (n = 1) and neurological involvement (n = 2). TCZ yielded rapid and maintained improvement in all ocular parameters of the patients, with complete remission in eight of them. However, this was not the case for the extraocular manifestations, since TCZ was only effective in three of them. After a mean (s.d.) follow-up of 9.5 (8.05) months, TCZ was withdrawn in two cases, due to a severe infusion reaction and arthritis impairment, respectively. CONCLUSION: TCZ could be a therapeutic option in patients with BD and refractory uveitis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study. Rheumatology (Oxford). 2018. PMID: 29471416. doi:10.1093/rheumatology/kex480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。